How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

681 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

281. Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Contraindications to metformin and/or sulfonylurea according to the local label for those patients that enter the study with the respective background therapy Blood dyscrasias or any disorders causing haemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anaemia) Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight

2010 Clinical Trials

282. Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

with anti-obesity drugs (e.g. sibutramine, mazindol) 12 weeks prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT

2010 Clinical Trials

283. 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

and respective restrictions in Section 4.2.2 Treatment with rosiglitazone, pioglitazone, GLP-1 analogues, or insulin within 3 months prior to informed consent Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent Alcohol or drug abuse within the 3 months prior to informed consent or history of alcoholism Current treatment with systemic corticosteroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent

2010 Clinical Trials

284. Planned CORR: Planned Care for Obesity and Risk Reduction

psychiatric disorder that would impair compliance with the study protocol (e.g. unstable depression, bipolar, schizophrenia). Is not pregnant or does not intend to become pregnant during the 2-year study period. Is not currently taking weight-altering medications (e.g. Sibutramine (Meridia), Orlistat (Xenical, Alli)), and has not taken them in at least 3 months. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact

2010 Clinical Trials

285. Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea

carcinoma) and/or treatment for cancer within the last 5 years Contraindications to metformin and/or sulfonylurea according to the local label for those patients that enter the study with the respective background therapy Blood dyscrasias or any disorders causing haemolysis or unstable Red Blood Cell (e.g.malaria, babesiosis, haemolytic anaemia) Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery

2010 Clinical Trials

286. Effect of Milnacipran in Chronic Neuropathic Low Back Pain

insufficiency History of, or current, substance abuse/dependence Significantly abnormal laboratory values Pregnant or lactating any time during the course of the study Known sensitivity to Savella or other SNRI Glaucoma Taking any MAOI, sibutramine, digoxin, tricyclic antidepressants, other SNRI, Opioids. Beck Depression Inventory Score >30 Current Sleep Disorder Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact

2010 Clinical Trials

287. The Effect of the Treatment Program "Dr. Fedon Lindbergs Vektcoach" on Body Weight and Composition and Hormonal Profile

: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Body Mass Index (BMI)>35 BMI>27 + one risk factor for cardiovascular disease or metabolic syndrome >18 years Exclusion Criteria: Medicinal treatment of thyroid disease Pregnancy or planned pregnancy Taking of diet pills like Xenical or Sibutramine Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your

2010 Clinical Trials

288. Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

years . Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells (e.g. malaria, babesiosis, haemolytic anaemia). Contraindications to pioglitazone according to the local label. Contraindication to pioglitazone and/or metformin (relevant only for those patients who enter the study with both these background therapies) according to the local labels. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment

2010 Clinical Trials

289. Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

to the investigational product or its excipients. Treatment with insulin within 3 months prior to informed consent. Treatment with anti-obesity drugs (e.g., sibutramine, orlistat, rimonabant) within three months prior to informed consent or initiating therapy during the study. Any prior use of dipeptidyl peptidase-4 (DPP-4) inhibitors. Glucagon-like peptide-1 (GLP-1) agonists are excluded 3 months prior to informed consent. History of alcohol or drug abuse within 3 months prior to informed consent that would

2010 Clinical Trials

290. Cholesterol Absorption Inhibition Study

antidepressants, narcotic analgesics, adrenergic agents, calcium channel blockers) Concomitant medication that can alter intestinal transit (e.g. loperamide, chemical/ osmotic/bulk laxatives), or influence satiety/energy intake (e.g. sibutramine, gluco¬corticoids, anabolic steroids) Intolerance or allergy for test product. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact

2010 Clinical Trials

291. BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

malabsorption Blood dyscrasias or any disorders causing haemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anemia) Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years Contraindications to background therapy according to the local label Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc

2010 Clinical Trials

292. Cardiovascular co-medication among users of antiobesity drugs: a population-based study Full Text available with Trip Pro

Cardiovascular co-medication among users of antiobesity drugs: a population-based study The purpose of this study was to investigate to what extent patients using prescription antiobesity drugs (orlistat, sibutramine and rimonabant) used cardiovascular and antidiabetic drugs. An additional aim was to investigate whether such co-medication differed according to gender, age and amount of antiobesity drugs used.Data were retrieved from the Norwegian Prescription Database (NorPD). All patients who

2010 Pharmacy World & Science

293. Nonsurgical weight loss for extreme obesity in primary care settings: results of the Louisiana Obese Subjects Study. Full Text available with Trip Pro

behavioral counseling, structured diet, and choice of pharmacotherapy (sibutramine hydrochloride, orlistat, or diethylpropion hydrochloride) during months 3 to 7 and continued use of medications and maintenance strategies for months 8 to 24.The mean age of participants was 47 years; 83% were women, and 75% were white. Retention rates were 51% for the IMI group and 46% for the UCC group (P = .30). After 2 years, the results were as follows: (1) among 390 randomized participants, 31% in the IMI group

2010 Archives of internal medicine Controlled trial quality: uncertain

294. Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control

with rosiglitazone or pioglitazone within 3 months prior to informed consent Treatment with Glucagon-like peptide 1(GLP-1) analogues (e.g. exenatide) , Dipeptidyl-Peptidase 4(DPP-IV) inhibitor within 3 months prior to informed consent Treatment with insulin within 3 months prior to informed consent Treatment with anti-obesity drugs (e.g. sibutramine, orlistat, rimonabant) within 3 months prior to informed consent Alcohol abuse within the 3 months prior to informed consent that would interfere with trial

2010 Clinical Trials

295. Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy

Treatment with rosiglitazone or pioglitazone within 3 months prior to informed consent Treatment with an injectable Glucagon-like peptide- 1 (GLP-1) analogue (e.g. exenatide) , Dipeptidyl-Peptidase 4 (DPP-IV) inhibitor within 3 months prior to informed consent Treatment with insulin within 3 months prior to informed consent Treatment with anti-obesity drugs (e.g. sibutramine, orlistat, rimonabant) within 3 months prior to informed consent. Alcohol abuse within the 3 months prior to informed consent

2010 Clinical Trials

296. Expanding the definition of hypothalamic obesity. (Abstract)

. Dys-regulation of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) activity and melatonin may also have a role in the development of HyOb. The complexity of the syndrome requires simultaneous targeting of several mechanisms that are deranged in the HyOb patient. We review the studies evaluating possible treatment strategies, including sympathomimetics, somatostatin analogues, triiodothyronine, sibutramine, and surgery.© 2010 The Authors. obesity reviews © 2010 International Association for the Study

2010 Obesity Reviews

297. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. (Abstract)

, through diet, lifestyle changes and/or medications including orlistat, sibutramine, rimonabant or bariatric surgery, increase adiponectin and may improve liver histology. Insulin sensitizers, including pioglitazone and rosiglitazone, and lipid-lowering agents, including statins and fibrates, also upregulate adiponectin and ameliorate liver histology. The wider use of new treatment approaches appears to signal the dawn of a new era in the management of NAFLD. In this adiponectin-focused review

2010 obesity & metabolism

298. Isocaloric Dietary Interventions for Insulin Resistance and the Metabolic Syndrome

of chronic glucocorticoid use, oral glucocorticoid use for more than 5 days in the previous year, or anticipated treatment with oral or intravenous glucocorticoids during the study period. Daily, low-dose, inhaled or nasal glucocorticoids may be acceptable in some cases, at the discretion of the Principal Investigator. Current treatment with over-the-counter or prescription weight loss medications, such as orlistat or sibutramine History of bariatric surgery Current treatment with any cholesterol

2009 Clinical Trials

299. Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

contained in these agents If taking metformin and have a contraindication to metformin use Have been treated within 8 weeks of study start with systemic glucocorticoid therapy by oral, intravenous, intra-articular, or intramuscular route Have been treated with drugs that promote weight loss (e.g., Xenical® [orlistat], Meridia® [sibutramine], Acomplia® [rimonabant], Acutrim® [phenylpropanolamine], or similar over-the-counter medications) within 3 months of study start Have taken any of the following

2009 Clinical Trials

300. SUCCESS Tracking Study

., SSRIs, steroids, Ritalin) Taking prescription weight-loss drugs (Phentermine, Sibutramine, Orlistat, etc…) Have undergone, or plan to undergo, weight loss surgery (e.g. gastric bypass, lap band, duodenal switch) in the next 6 1/3 years Plan to undergo weight-altering cosmetic surgery procedures (e.g. breast reduction/augmentation, tummy tuck, liposuction, or other skin removal procedures) in the next 6 1/3 years Contacts and Locations Go to Information from the National Library of Medicine To learn

2009 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>